

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

AMNEAL PHARMACEUTICALS LLC and AMNEAL  
PHARMACEUTICALS OF NEW YORK, LLC  
Petitioners,

v.

ALMIRALL, LLC,  
Patent Owner.

---

Case IPR2019-00207  
Patent 9,517,219 B2

---

Before SUSAN L. C. MITCHELL, CHRISTOPHER G. PAULRAJ, and  
RYAN H. FLAX, *Administrative Patent Judges*.

FLAX, *Administrative Patent Judge*.

DECISION  
Institution of *Inter Partes* Review  
35 U.S.C. § 314

Almirall, LLC (“Patent Owner”) is the owner of U.S. Patent No. 9,517,219 B2 (Ex. 1001, “the ’219 patent”). Amneal Pharmaceuticals LLC, and Amneal Pharmaceuticals of New York, LLC (collectively, “Petitioners”) filed a Petition requesting *inter partes* review of claims 1–8 of the ’219 patent. Paper 3 (“Pet.”). Patent Owner, in turn, filed a Preliminary Response. Paper 8 (“Prelim. Resp.”). Further, pursuant to our authorization, Petitioners and Patent Owner filed a Reply and a Sur-reply, respectively. Papers 10, 11.

Under 37 C.F.R. § 42.4(a), we have authority to determine whether to institute an *inter partes* review. We may institute an *inter partes* review if the information presented in the petition filed under Section 311, and any response filed under Section 313, shows that there is a reasonable likelihood that the Petitioners would prevail with respect to at least one of the claims challenged in the petition. 35 U.S.C. § 314. After reviewing the parties’ submissions, we conclude that Petitioners have demonstrated a reasonable likelihood that they would prevail in showing at least one claim of the ’219 patent is unpatentable. Therefore, we institute *inter partes* review of all aforementioned claims on all grounds raised in the petition, pursuant to 35 U.S.C. § 314; *see also* Guidance on the Impact of SAS on AIA Trial Proceedings (April 26, 2018) (available at <https://www.uspto.gov/patents-application-process/patent-trial-and-appealboard/trials/guidance-impact-sas-aia-trial>).

I. BACKGROUND

A. *RELATED MATTERS*

Petitioners have disclosed:

The following matters would affect, or be affected by, a decision in this proceeding: (1) IPR2018-00608, challenging claims of the related [U.S. Patent 9,161,926], which are directed to the same topical dapsons compositions as the '219 patent; and (2) *Almirall, LLC v. Taro Pharmaceutical Industries Ltd.*, C.A.[.] 1-17-cv-00663 (consolidated) (D.Del.), to which[, the district court case,] Petitioners are not a party.

Pet. 64–65. Patent Owner identifies the same related matters. *See* Patent Owner's Mandatory Notices (filed Jan. 10, 2019) (Paper 5).

B. *THE CLAIMED INVENTION*

The invention claimed in the '219 patent relates to a method for treating at least one of acne vulgaris or rosacea by administering a compound including dapsons, diethylene glycol (also called ethoxydiglycol, diethylene glycol monoethyl ether, and DGME), acrylamide/sodium acryloyldimethyl taurate copolymer (also identified by the commercial product name Sepineo P 600), and water, but not including adapalene.

Ex. 1001, 15:40–16:13. The '219 patent's abstract states:

Dapsons and dapsons/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsons and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsons to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder.

*Id.* at Abstract. The specification of the '219 patent further states:

Dapsone, (4,4'-diaminodiphenyl sulfone) is a medicament possessing several beneficial medicinal activities. Dapsone is typically administered as one of the medicinal agents used in the treatment of leprosy. Dapsone and its derivatives are also effective for treatment of bacterial infections, protozoal infections such as malaria, *pneumocystis carinii*, and plasmonic infections such as toxoplasmosis.

Dapsone is also useful as an anti-inflammatory agent. It has been used to treat skin diseases characterized by the abnormal infiltration of neutrophils, such as Dermatitis herpeticiformis, linear IgA dermatosis, pustular psoriasis, pyoderma gangrenosum, acne vulgaris, and Sweet's Syndrome.

*Id.* at 2:12–24.

Regarding the additional claimed components used in the claimed acne/rosacea-treating method, the '219 patent states, “[d]iethylene glycol monoethyl ether is a solubilizer for dapsone, thereby allowing compositions to be prepared with increased solubilized concentrations of dapsone.” *Id.* at 2:48–50. The '219 patent further states:

use of a polymeric viscosity builder minimizes the intensity of yellowing of the composition caused by the increased solubility of dapsone in diethylene glycol monoethyl ether. In addition, the polymeric viscosity builder influences dapsone crystallization. This, in turn, results in compositions with improved aesthetics (i.e., reduction in particle size which minimizes “gritty” feeling upon application).

*Id.* at 2:54–61. Regarding this polymeric viscosity builder, the '219 patent further states, “[i]n some embodiments, the polymeric viscosity builder is an acrylamide/sodium acryloyldimethyltaurate copolymer, and further includes isohexadecane, sorbitan oleate, water, and Polysorbate 80.” *Id.* at 5:47–50. The '219 patent describes 62 different “embodiments” where various amounts of these, and other, components are provided for an acne/rosacea-

treating composition. *Id.* at 6:58–12:40. The '219 patent also describes eight different “examples” of formulations including these, and other, components. *Id.* at 12:42–15:33.

The '219 patent has eight claims, of which claims 1 and 6 are independent claims. Independent claims 1 and 6 are illustrative and reproduced below:

**1.** A method for treating a dermatological condition selected from the group consisting of acne vulgaris and rosacea comprising administering to a subject having the dermatological condition selected from the group consisting of acne vulgaris and rosacea a topical pharmaceutical composition comprising:

about 7.5% w/w dapsone;

about 30% w/w to about 40% w/w diethylene glycol monoethyl ether;

about 2% w/w to about 6% w/w of a polymeric viscosity builder comprising acrylamide/sodium acryloyldimethyl taurate copolymer; and

water;

wherein the topical pharmaceutical composition does not comprise adapalene.

**6.** A method for treating a dermatological condition selected from the group consisting of acne vulgaris and rosacea comprising administering to a subject having the dermatological condition selected from the group consisting of acne vulgaris and rosacea a topical pharmaceutical composition comprising:

about 7.5% w/w dapsone;

about 30% w/w diethylene glycol monoethyl ether;

about 4% w/w of a polymeric viscosity builder comprising acrylamide/sodium acryloyldimethyl taurate copolymer; and

water;

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.